Immunotherapy. 2023 Nov 27. doi: 10.2217/imt-2023-0116. Online ahead of print.

Jacopo Fanizza ¹, Ferdinando D'Amico ^1 2, Gaetano Lauri ¹, Samuel J Martinez-Dominguez ³, Mariangela Allocca ¹, Federica Furfaro ¹, Alessandra Zilli ¹, Gionata Fiorino ¹, Tommaso Lorenzo Parigi ¹, Simona Radice ¹, Laurent Peyrin-Biroulet ^4 5, Silvio Danese ¹

Author information

¹Department of Gastroenterology & Endoscopy, IRCCS San Raffaele Hospital & Vita-Salute San Raffaele University, Milan, Italy.

²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

³Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Aragón Health Research Institute, Zaragoza, Spain; School of Medicine, University of Zaragoza, Spain.

⁴University of Lorraine, Inserm, NGERE, F-54000 Nancy, France.

⁵Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France.

Abstract

Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn's disease (CD). The purpose of this review is to summarize the available data regarding filgotinib in the management of UC and CD. We used Pubmed, Embase and clinicaltrials.gov websites to search all available data and currently ongoing studies regarding the efficacy and safety of filgotinib in inflammatory bowel diseases. Filgotinib is an effective and safe drug for the management of biologic-naive and biologic-experienced patients with moderate-to-severe UC. The same efficacy results have not been achieved in CD.